# CYTEK BIOSCIENCES, INC. (CTKB) · Edgar & Edgarette company card

> Cytek Biosciences (CTKB) grew revenue 0.5% in FY2025 to $201 million, operating margin -20.0% against a -1.0% median for laboratory analytical instruments, equity 74.0% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1831915 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/CTKB) · [JSON](https://www.pops4.com/boards/company/CTKB.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $201M |
| Revenue growth, 1 year | 0.5% |
| Revenue growth per year | 12.0% |
| Operating margin | -20.0% (prior year -10.2%) |
| Net margin | -33.0% |
| Operating cash flow | −$5M |
| Capital spending | $4M |
| Free cash flow | −$9M |
| Cash | $91M |
| Long-term debt | — |
| Total assets | $462M |
| Total equity | $342M |
| Equity ÷ assets | 74.0% |
| Return on equity | -19.5% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: 6.15 (safe zone)
- Piotroski F: 4 of 9 (middling)
- Beneish M: -3.29 (below the −1.78 line)
- Health Harbor boat: Weathered boat · two warning signs · operating cash flow was negative; operating loss: a margin of -20.0% in FY2025
- Cash Compass: In between · no clear cash pattern yet

## Edgarette's reading

Exposure: revenue $201.5M (FY2025). Experience: revenue up 0.5% on the year, up 12.0% a year over 4 years; operating margin -20.0%, down from -10.2%. Soundness: equity 74.0% of assets, return on equity -19.5%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $172.0M and $244.7M next year (method v4.1: its own 4-year record of growth weighed at 50% against $100M–1B filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $157.3M to $268.5M. A statistical range, not company guidance. Against peers (12 filers, $50M+ revenue, laboratory analytical instruments): operating margin -20.0% against a -1.0% median; growth 0.5% against 1.1%.

Range logged 2026-09-30, receipt 639bd706da9dbbbd, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 3, latest 2026-07-15 ([filing](https://www.sec.gov/Archives/edgar/data/1831915/000119312526304789/0001193125-26-304789-index.htm))

## Recent filings

- 10-Q · filed 2026-11-04 · [filing](https://www.sec.gov/Archives/edgar/data/1831915/000162828026070259/0001628280-26-070259-index.htm)
- 8-K · filed 2026-11-04 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1831915/000119312526447300/0001193125-26-447300-index.htm)
- 8-K · filed 2026-09-29 · 5.03 Amendments to Articles or Bylaws; Change in Fiscal Year; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1831915/000119312526407330/0001193125-26-407330-index.htm)
- 8-K · filed 2026-08-24 · 7.01 Regulation FD Disclosure; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1831915/000119312526361705/0001193125-26-361705-index.htm)
- 10-Q · filed 2026-08-05 · [filing](https://www.sec.gov/Archives/edgar/data/1831915/000162828026053496/0001628280-26-053496-index.htm)
- 8-K · filed 2026-08-05 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1831915/000119312526335212/0001193125-26-335212-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001831915.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1831915

## Cite

POPS4, Edgar & Edgarette: CYTEK BIOSCIENCES, INC. (CTKB) company card, from the company's own SEC filings, accessed 2026-11-14, https://www.pops4.com/boards/company/CTKB. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.